ArticleDrugs in context2021

The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study.

Sergey V Efimov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.